What AI says about EarlyDiagnostics

EarlyDiagnostics (EarlyDx) is building a platform that converts cell-free DNA into whole-body molecular insights using its proprietary MethylScan epigenomic technology, enabling early disease detection, patient risk stratification, precision medicine, and longitudinal health monitoring from a single blood draw. The company offers CancerRadar, a blood test for highly accurate cancer detection and localization, and EarlyDx-Cloud, a one-stop bioinformatics solution to support liquid biopsy-based diagnostics, therapy selection, and treatment monitoring. Its technologies also include cfSNV for calling mutations from blood and cfTrack for non-invasive monitoring of MRD, recurrence, and evolution across oncology and liver disease.